See more : Kyowakogyosyo Co.,Ltd. (5971.T) Income Statement Analysis – Financial Results
Complete financial analysis of Citius Pharmaceuticals, Inc. (CTXR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Citius Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Atec, Inc. (ATCN) Income Statement Analysis – Financial Results
- PT Fast Food Indonesia Tbk (FAST.JK) Income Statement Analysis – Financial Results
- Kirloskar Industries Limited (KIRLOSIND.NS) Income Statement Analysis – Financial Results
- IronRidge Resources Limited (IRR.L) Income Statement Analysis – Financial Results
- Maverix Metals Inc. (MMX.TO) Income Statement Analysis – Financial Results
Citius Pharmaceuticals, Inc. (CTXR)
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -194.32K | -179.68K | -164.87K | -152.36K | -893.00 | -1.75K | -2.63K | -1.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.82M | 17.66M | 12.24M | 8.81M | 8.60M | 6.56M | 2.94M | 2.93M | 1.80M | 437.97K | 492.14K | 705.81 | 0.00 |
| General & Administrative | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 310.30 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.31K | 0.00 |
| SG&A | 21.91M | 15.66M | 11.29M | 8.90M | 7.00M | 7.23M | 7.05M | 4.52M | 1.43M | 715.03K | 28.12K | 19.62K | 25.64K |
| Other Expenses | 0.00 | 1.45M | 59.92K | 110.21K | 715.98K | 1.27M | 732.15K | 732.15K | 486.27K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Cost & Expenses | 36.73M | 33.32M | 23.53M | 17.71M | 15.60M | 13.79M | 9.99M | 7.45M | 3.23M | 1.14M | 28.12K | 19.62K | 25.64K |
| Interest Income | 1.18M | 251.40K | 261.83K | 68.07K | 52.66K | 0.00 | 806.00 | 806.00 | 3.07K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 251.40K | 10.84K | 15.67K | 16.44K | 15.84K | 850.79K | 8.99K | 7.50K | 0.00 | 3.25K | 2.39K | 0.00 |
| Depreciation & Amortization | 194.32K | 179.68K | 164.87K | 152.36K | 893.00 | 1.75K | 2.63K | 1.34K | 3.07K | 1.15M | 1.18M | 1.02K | 704.00 |
| EBITDA | -36.73M | -32.88M | -22.88M | -17.38M | -15.54M | -13.79M | -9.98M | -7.45M | -3.23M | 0.00 | 0.00 | -19.62K | -24.93K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -36.73M | -33.32M | -23.53M | -17.71M | -15.60M | -13.79M | -9.99M | -7.45M | -3.23M | -1.15M | -28.12K | -19.62K | -25.64K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.77M | 251.40K | 477.46K | 162.60K | 36.22K | 1.25M | -398.64K | -846.41K | 327.66K | 171.82K | 0.00 | -2.39K | -704.00 |
| Income Before Tax | -31.97M | -33.06M | -23.05M | -17.55M | -15.56M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 576.00K | 576.00K | 70.76K | 125.88K | 16.44K | 1.28M | 850.79K | 8.99K | 4.43K | -119.15K | -1.18M | -1.02K | 0.00 |
| Net Income | -32.54M | -33.64M | -23.13M | -17.67M | -15.58M | -12.54M | -10.38M | -8.30M | -2.90M | -1.27M | -31.37K | -22.01K | -26.34K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.23 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| EPS Diluted | -0.22 | -0.23 | -0.21 | -0.45 | -0.77 | -1.17 | -1.89 | -2.29 | -1.37 | 0.00 | -0.04 | -0.03 | -0.04 |
| Weighted Avg Shares Out | 146.13M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
| Weighted Avg Shares Out (Dil) | 151.29M | 146.08M | 108.60M | 39.17M | 20.16M | 10.73M | 5.48M | 3.62M | 2.12M | 0.00 | 750.00K | 750.00K | 750.00K |
Citius Pharmaceuticals Introduces Milo-Lok
Specialty pharmaceutical company Citius Pharmaceuticals is dedicated to developing and commercializing therapeutic products for growing markets. Citius' President and CEO Myron Holubiak spoke about the company's four pipeline programs – Milo-Lok, Halo-Lido, Mino-Wrap and iMSC – at the Benzinga Global...
Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting
CRANFORD, N.J., May 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique...
Penny Stocks to Buy? 3 That WallStreetBets Won't Stop Talking About
3 penny stocks that are wildly popular on Reddit and WallStreetBets The post Penny Stocks to Buy? 3 That WallStreetBets Won't Stop Talking About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy
CRANFORD, N.J., May 18, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique...
G.research Hosts Its Inaugural Micro-Cap Conference
RYE, N.Y.--(BUSINESS WIRE)--G.research will host its inaugural Micro-Cap Symposium on May 18, 2021. The conference will be held virtually. This research meeting will feature presentations by senior management spanning various sectors. Investors should contact their salesperson for more information or...
Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations
CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.
G.research to Host Its Inaugural Micro-Cap Symposium on May 18, 2021
RYE, N.Y.--(BUSINESS WIRE)--G.research will host its inaugural Micro-Cap Symposium on May 18, 2021. The conference will be held virtually. This research meeting will feature presentations by senior management spanning various sectors. Investors should contact their salesperson for more information or...
5 Reddit Penny Stocks Seeing the Most Chatter Friday
InvestorPlace is closing out a busy week of trading with a look at the Reddit penny stocks seeing the most chatter on Friday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Friday appeared first on InvestorPlace.
EXCLUSIVE: Citius Pharmaceuticals CEO Myron Holubiak Talks Company Advantages
Myron Holubiak, president and CEO of Citius Pharmaceuticals Inc (NASDAQ: CTXR), appeared Thursday at Benzinga's Global Small Cap Conference for an exclusive interview. The name Citius Pharmaceuticals comes from the Olympic motto "Citius, Altius, Fortius," which is Latin for "Faster, Higher, Stronger," Holubiak told...
Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update
CRANFORD, N.J., May 13, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today reported financial results for the second fiscal quarter of 2021 and provided a general business update.
Source: https://incomestatements.info
Category: Stock Reports